Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L, Mohammad MA, Milazzo G, Moreno-Smith M, Patel TD, Zorman B, Badachhape A, Hernandez BE, Wolf AB, Zeng Z, Foster JH, Aloisi S, Sumazin P, Zu Y, Hicks J, Ghaghada KB, Putluri N, Perini G, Coarfa C, Barbieri E. Tao L, et al. Among authors: foster jh. Nat Commun. 2022 Jun 28;13(1):3728. doi: 10.1038/s41467-022-31331-2. Nat Commun. 2022. PMID: 35764645 Free PMC article.
Neuroblastoma.
Shohet J, Foster J. Shohet J, et al. BMJ. 2017 May 3;357:j1863. doi: 10.1136/bmj.j1863. BMJ. 2017. PMID: 28468760 No abstract available.
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H, Yu Y, Zhao Y, Wu D, Yu X, Lu J, Chen Z, Zhang H, Hu Y, Zhai Y, Su J, Aheman A, De Las Casas A, Jin J, Xu X, Shi Z, Woodfield SE, Vasudevan SA, Agarwal S, Yan Y, Yang J, Foster JH. Li H, et al. Among authors: foster jh. Cancer Lett. 2019 Aug 10;457:129-141. doi: 10.1016/j.canlet.2019.05.011. Epub 2019 May 14. Cancer Lett. 2019. PMID: 31100410
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Ting MA, Reuther J, Chandramohan R, Voicu H, Gandhi I, Liu M, Cortes-Santiago N, Foster JH, Hicks J, Nuchtern J, Scollon S, Plon SE, Chintagumpala M, Rainusso N, Roy A, Parsons DW. Ting MA, et al. Among authors: foster jh. J Pathol. 2021 Sep;255(1):52-61. doi: 10.1002/path.5736. Epub 2021 Jul 7. J Pathol. 2021. PMID: 34086347
Characteristics of benign neuroblastic tumors: Is surgery always necessary?
Whitlock RS, Mehl SC, Larson SK, Foster JH, Hicks J, Nuchtern JG, Sher AC, Vasudevan SA, Naik-Mathuria B. Whitlock RS, et al. Among authors: foster jh. J Pediatr Surg. 2022 Aug;57(8):1538-1543. doi: 10.1016/j.jpedsurg.2021.07.002. Epub 2021 Jul 7. J Pediatr Surg. 2022. PMID: 34281709
High-Risk Neuroblastoma Treatment Review.
Smith V, Foster J. Smith V, et al. Children (Basel). 2018 Aug 28;5(9):114. doi: 10.3390/children5090114. Children (Basel). 2018. PMID: 30154341 Free PMC article. Review.
Blood product administration during high risk neuroblastoma therapy.
Silverstein A, Reddy K, Smith V, Foster JH, Russell HV, Whittle SB. Silverstein A, et al. Among authors: foster jh. Pediatr Hematol Oncol. 2020 Feb;37(1):5-14. doi: 10.1080/08880018.2019.1668095. Epub 2019 Dec 12. Pediatr Hematol Oncol. 2020. PMID: 31829069 Free PMC article.
333 results